What is Artrya Limited's main product?

Artrya's main product is Salix, an AI-powered software for diagnosing coronary artery disease using CTA scans. Learn more at their official site [here](https://www.artrya.com).

How has AYA.AX performed recently?

Artrya Limited has risen 6.45% pre-market, trading at A$3.96, with volumes exceeding average levels, suggesting increased investor interest due to AI advancements.

What is Meyka AI's rating for AYA.AX?

Meyka AI rates AYA.AX with a score of 66.71 and a grade 'B', recommending a 'HOLD' based on various performance metrics and forecasts. Explore more detail at Meyka [here](https://meyka.com/stocks/AYA.AX).

What are the technical indicators for AYA.AX?

Key indicators include an RSI of 62.63, MACD of 0.19, and bullish momentum suggesting the stock is approaching overbought conditions. Always consider multiple metrics for a comprehensive analysis.

What does Meyka AI forecast for AYA.AX?

Meyka AI projects AYA.AX to reach A$4.44 in the next month, with longer-term forecasts indicating further growth. These projections are subject to market conditions and are not guarantees.

AU Stocks

AYA.AX Pre-Market (21 Dec 2025): AI-Driven Gains Continue

ByHuzaifa Zahoor December 21, 2025December 21, 2025

Artrya Limited (ASX:AYA) has caught the market’s attention with a pre-market surge of over 6%. This surge is attributed to the company’s innovative use of artificial intelligence to revolutionize healthcare diagnostics.